Abstract：
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) infections are considered an important public health problem, and treatment options are limited. Accordingly, in this meta-analysis, we analyzed published studies to survey in vitro activity of recently approved antibiotics against MRSA isolates.
METHODS: We searched electronic databases; PubMed, Scopus, and Web of Science to identify relevant studies (until November 30, 2020) that have focused on the in vitro activity of telavancin, dalbavancin, oritavancin, and tedizolid against MRSA isolates. Statistical analyses were conducted using STATA software (version 14.0).
RESULTS: Thirty-eight studies were included in this meta-analysis. Overall in vitro activity of tedizolid on 12,204 MRSA isolates was 0.250 and 0.5 µg/mL for MIC50 and MIC90, (minimum inhibitory concentration at which 50% and 90% of isolates were inhibited, respectively), respectively. The overall antibacterial activity of dalbavancin on 28539 MRSA isolates was 0.060 and 0.120 µg/mL for MIC50 and MIC90, respectively. The overall antibacterial activity of oritavancin on 420 MRSA isolates was 0.045 and 0.120 µg/mL for MIC50 and MIC90, respectively. The overall antibacterial activity of telavancin on 7353 MRSA isolates was 0.032 and 0.060 µg/mL for MIC50 and MIC90, respectively. The pooled prevalence of tedizolid, telavancin, and dalbavancin susceptibility was 100% (95% CI: 100-100).
CONCLUSIONS: Telavancin, dalbavancin, oritavancin, and tedizolid had potent in vitro activity against MRSA isolates. The low MICs and high susceptibility rates of these antibiotics recommend a hopeful direction to introduce useful antibiotics in treating MRSA infections in the future.
METHODS: We searched electronic databases; PubMed, Scopus, and Web of Science to identify relevant studies (until November 30, 2020) that have focused on the in vitro activity of telavancin, dalbavancin, oritavancin, and tedizolid against MRSA isolates. Statistical analyses were conducted using STATA software (version 14.0).
RESULTS: Thirty-eight studies were included in this meta-analysis. Overall in vitro activity of tedizolid on 12,204 MRSA isolates was 0.250 and 0.5 µg/mL for MIC50 and MIC90, (minimum inhibitory concentration at which 50% and 90% of isolates were inhibited, respectively), respectively. The overall antibacterial activity of dalbavancin on 28539 MRSA isolates was 0.060 and 0.120 µg/mL for MIC50 and MIC90, respectively. The overall antibacterial activity of oritavancin on 420 MRSA isolates was 0.045 and 0.120 µg/mL for MIC50 and MIC90, respectively. The overall antibacterial activity of telavancin on 7353 MRSA isolates was 0.032 and 0.060 µg/mL for MIC50 and MIC90, respectively. The pooled prevalence of tedizolid, telavancin, and dalbavancin susceptibility was 100% (95% CI: 100-100).
CONCLUSIONS: Telavancin, dalbavancin, oritavancin, and tedizolid had potent in vitro activity against MRSA isolates. The low MICs and high susceptibility rates of these antibiotics recommend a hopeful direction to introduce useful antibiotics in treating MRSA infections in the future.
摘要：
背景：耐甲氧西林金黄色葡萄球菌（MRSA）感染被认为是重要的公共卫生问题，和治疗选择是有限的。因此，在这个荟萃分析中，我们分析了已发表的研究,以调查最近批准的抗生素对MRSA分离株的体外活性.
方法：我们搜索了电子数据库；PubMed，Scopus,和WebofScience确定相关研究（直到2020年11月30日），这些研究侧重于telavancin的体外活性，dalbavancin,oritavancin,和替地唑胺对抗MRSA分离株。使用STATA软件（14.0版）进行统计分析。
结果：本荟萃分析纳入了38项研究。对于MIC50和MIC90，替地唑胺对12,204株MRSA分离株的总体体外活性为0.250和0.5µg/mL（抑制50％和90％分离株的最小抑制浓度，分别)，分别。对于MIC50和MIC90，达巴万星对28539个MRSA分离株的总体抗菌活性分别为0.060和0.120µg/mL。对于MIC50和MIC90，奥利万星对420种MRSA分离株的总体抗菌活性分别为0.045和0.120µg/mL。telavancin对7353个MRSA分离株的总体抗菌活性对于MIC50和MIC90分别为0.032和0.060µg/mL。替迪唑胺的合并患病率，Telavancin,达巴万星敏感性为100%(95%CI:100-100)。
结论：Telavancin，dalbavancin,oritavancin,和替地唑胺对MRSA分离株具有有效的体外活性。这些抗生素的低MIC和高敏感性为将来在治疗MRSA感染中引入有用的抗生素提供了有希望的方向。
方法：我们搜索了电子数据库；PubMed，Scopus,和WebofScience确定相关研究（直到2020年11月30日），这些研究侧重于telavancin的体外活性，dalbavancin,oritavancin,和替地唑胺对抗MRSA分离株。使用STATA软件（14.0版）进行统计分析。
结果：本荟萃分析纳入了38项研究。对于MIC50和MIC90，替地唑胺对12,204株MRSA分离株的总体体外活性为0.250和0.5µg/mL（抑制50％和90％分离株的最小抑制浓度，分别)，分别。对于MIC50和MIC90，达巴万星对28539个MRSA分离株的总体抗菌活性分别为0.060和0.120µg/mL。对于MIC50和MIC90，奥利万星对420种MRSA分离株的总体抗菌活性分别为0.045和0.120µg/mL。telavancin对7353个MRSA分离株的总体抗菌活性对于MIC50和MIC90分别为0.032和0.060µg/mL。替迪唑胺的合并患病率，Telavancin,达巴万星敏感性为100%(95%CI:100-100)。
结论：Telavancin，dalbavancin,oritavancin,和替地唑胺对MRSA分离株具有有效的体外活性。这些抗生素的低MIC和高敏感性为将来在治疗MRSA感染中引入有用的抗生素提供了有希望的方向。
